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IntroductIon
Prostate cancer (PCa) is the most commonly 
diagnosed malignancy in men, as a result of population 
aging [1] and PSA testing, which has favored early detection 
but also overdiagnosis and overtreatment.
Unlike the well-characterized pathway of acquired 
mutations displayed by colon cancer, there is not a 
clearly defined unique pathway for the development 
and progression of malignant disease in the prostate 
[2, 3]. A distinguishing feature is the heterogeneous 
and multifocal nature of PCa, with a juxtaposition 
of hyperplastic and preneoplastic (PIN) lesions 
with neoplastic foci of various degree of malignant 
progression. This suggests that PCa development is the 
combined result of genetic and epigenetic alterations in 
the cells of origin and changes in their communication 
with their environment [4–7].
The Notch signaling pathway is an important 
form of cell-cell communication that plays a key role in 
control of cell fate, stem cell potential and differentiation 
[8]. The Notch gene family (Notch1, 2, 3, 4) consists 
of evolutionary conserved transmembrane receptors. 
Interactions with ligands of the Delta and Jagged families 
present on the surface of neighboring cells trigger 
proteolytic cleavage of these receptors with release 
of their intracellular region. The best characterized 
“canonical” pathway of Notch activation involves 
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AbstrAct
Adenocarcinomas of the prostate arise as multifocal heterogeneous lesions 
as the likely result of genetic and epigenetic alterations and deranged cell-cell 
communication. Notch signaling is an important form of intercellular communication 
with a role in growth/differentiation control and tumorigenesis. Contrasting 
reports exist in the literature on the role of this pathway in prostate cancer (PCa) 
development. We show here that i) compared to normal prostate tissue, Notch1 
expression is significantly reduced in a substantial fraction of human PCas while it is 
unaffected or even increased in others; ii) acute Notch activation both inhibits and 
induces process networks associated with prostatic neoplasms; iii) down-modulation 
of Notch1 expression and activity in immortalized normal prostate epithelial cells 
increases their proliferation potential, while increased Notch1 activity in PCa cells 
suppresses growth and tumorigenicity through a Smad3-dependent mechanism 
involving p21WAF1/CIP1; iv) prostate cancer cells resistant to Notch growth inhibitory 
effects retain Notch1-induced upregulation of pro-oncogenic genes, like EPAS1 and 
CXCL6, also overexpressed in human PCas with high Notch1 levels. Taken together, 
these results reconcile conflicting data on the role of Notch1 in prostate cancer.
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translocation of this molecule to the nucleus, where it 
associates with the DNA binding protein CSL (CBF-1 or 
RBP-Jκ), converting it from a repressor into an activator 
of transcription [8, 9]. The biological function of the 
Notch pathway is highly context-dependent, as it can 
exert opposite roles in growth/differentiation of different 
cell types, at different developmental stages and/or under 
normal vs pathological conditions. In mammalian cells, 
increased Notch signaling has been previously implicated 
as a positive determinant of tumorigenesis, which is 
associated with the ability of this pathway to suppress 
differentiation [10–16]. However, in keratinocytes 
of mouse and human origin, Notch signaling plays 
the opposite function of promoting differentiation 
and suppressing tumor formation [17–19]. Prostate 
epithelial cells share some significant similarities with 
keratinocytes, including their distribution in stem cell 
and transit amplifying compartments, and cells at various 
stages of differentiation [20, 21]. In mouse prostate, 
inactivation of the Notch pathway disrupts normal 
commitment to differentiation and causes enhanced 
proliferation with features similar to early preneoplastic 
lesions [22]. Conflicting reports exist on a possible tumor 
suppressing or promoting function of Notch in (human) 
prostate cancer: several works suggest that Notch1 may 
act as a tumor suppressor in this specific tissue and its 
signalling is lost in prostate adenocarcinomas [22, 23]; 
other surveys have demonstrated that Notch1 expression 
augments in human prostate tumor specimens with 
increasing tumor grade and that Notch1 knockdown 
decreases cell invasion [24, 25]. Thus, an important 
question is whether these conflicting conclusions can be, 
at least to some extent, reconciled. A recent review by 
Carvalho and coworkers reveals that increased Notch1 
can confer a survival advantage on prostate cancer cells, 
but also that Notch1 signaling can antagonize growth 
and survival of both benign and malignant prostate cells 
[26]. In another review, Su and colleagues stress the 
need of future comprehensive studies to clarify the role 
of Notch signaling in PCa, which remains inconclusive 
until now [27].
Determining the cellular contexts where 
Notch1 promotes or suppresses prostate growth could 
open opportunities for diagnostic and therapeutic 
interventions. This is an important and urgent need, 
in view of the proposed use of anti-Notch compounds 
for cancer therapy, including prostate cancer [28]. 
We show here that, while increased Notch1 exerts a 
growth suppressing function in both human prostate 
primary epithelial cells and cancer cells, at the gene 
expression level it induces genes with opposite 
functions. One group of genes can contribute to growth/
tumor suppression, while a second group of genes has 
an opposite growth-promoting function, that can be 
unmasked in cells that become resistant to the Notch-
growth inhibitory effects.
results
notch1 expression and activity are consistently 
down-modulated in prostate cancer cell lines and 
a substantial fraction of prostate cancers but up-
regulated in others
Interrogating public data repositories (i.e. Oncomine, 
GEO, ArrayExpress and the cBioportal), we found 
conflicting information on levels of Notch1 mRNA in 
prostate cancer. In some datasets Notch1 expression was 
found significantly down-regulated [29–34] and (TCGA 
PRAD (Prostate Adenocarcinoma)), while in others it did 
not appear to change [35, 36] or even to increase [37]. 
We directly evaluated Notch1 mRNA levels in 41 
prostate adenocarcinomas and 10 age-matched controls 
(non tumor prostate tissues derived from the peripheral 
zone of the prostate gland) and in 3 independent prostate 
epithelial tumors versus normal matched tissues after laser 
capture microdissection (LCM), by RT-qPCR analysis. 
Interestingly, even though Notch1 expression levels were 
in average decreased in tumor samples when compared to 
normal ones, including LCM samples, some PCa samples 
showed low levels, while others unchanged or increased 
levels when compared to normal prostate tissues (Figure 
1A, 1B). This pattern of different Notch expression levels 
was also observed in Tomlins’ LCM dataset [31], assuring 
no bias due to stroma or non neoplastic epithelial tissue.
Decreased levels of Notch1 protein and mRNA 
expression were also found in several widely used prostate 
cancer cell lines (RWPE2, LNCaP, 22rv1, PC3 and DU145) 
relatively to primary prostate epithelial cells (PrEC or 
hPEC) or to an immortalized but non-tumorigenic prostate 
cell line (RWPE1) [38] (Figure 1C–1D). A majority of 
other prostate cell lines derived from a panel of benign and 
malignant disease also showed lower Notch1 levels relative 
to commercially available primary prostate epithelial cells 
(PrEC), as well as 3 other independently derived primary 
prostate epithelial cells (Figure 1E). There were no 
significant differences in Notch2 expression in the human 
tumors that we analyzed and levels of Notch2 mRNA were 
only slightly down-modulated in prostate cancer cell lines 
(data not shown).
Expression levels of “canonical” Notch target genes 
of the Hes/Herp family are commonly assessed as an 
indication of endogenous Notch activity. When assessed 
by RT-qPCR, Hes1 and Hey1 were found significantly 
decreased in approximately 70% of the prostate tumors 
that we examined (Figure 1A). However, there was only 
partial concordance between tumors with decreased 
Notch1 versus Hes1 or Hey1 levels (66% and 83% 
concordance, respectively). Co-occurrence analysis using 
the largest dataset available (TCGA-PRAD), yielded that 
Notch1 association with Hey1 is statistically significant 
(p-value = 0.004), as well as Notch1 association with 
Notch3 (p-value = 0.008), Notch4 (p-value = 0.0009) and 
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Jag2 (p-value = 0.00001). With Notch2 and Jag1, there is 
a tendency towards co-occurrence, however the p-value 
is greater than 0.01 (0.02 for Notch2 and 0.28 for Jag1).
Notch1 related expression profiling of clinical 
tumors reveals a dual pattern of gene expression
We compared expression profiles of PCa lesions 
with low versus high levels of Notch1, using our own 
(Chiorino) and 3 independent datasets [33, 36] (TCGA-
PRAD). GO analysis revealed an astonishingly similar 
pattern of affected biological processes, among the 4 
independent datasets. Genes up-regulated in tumors with 
Notch1 levels higher than normal tissue (Notch_high) 
were enriched in terms like cell migration, apoptosis, 
angiogenesis, neurogenesis and epithelial to mesenchymal 
transition, while fatty acid metabolism and nucleosome 
assembly were consistently overrepresented among the 
Figure 1: notch1 expression and activity are down-modulated in human prostate tumors and cancer cells lines. (A) Total 
RNA from 41 surgically excised prostate carcinomas were analyzed in parallel with 10 normal prostates and/or a commercially available 
pool of RNA extracted from organ donor healthy prostates for levels of Notch1, HEY1 and HES1 mRNA expression by real time RT-PCR. 
Results are expressed as log2 ratios of mRNA levels in the individual tumors versus the averaged values of normal prostate samples (using 
for each samples β-actin for internal normalization). Differences in gene expression below –0.5 are all statistically significant, as calculated 
by two sample unpaired Student t-test. (b) LCM-obtained epithelial cells from prostate tumor (T, n = 3) and normal prostate tissue (N, n= 3) 
samples from different individuals were analyzed by RT–qPCR for the Notch1 gene. (c) Human primary prostate epithelial cells (PrEC), 
immortalized prostate epithelial cells (RWPE1), a ras-induced tumorigenic derivative of RWPE1 cells (RWPE2; [38]), and the indicated 
prostate cancer cell lines (LnCaP, 22rv1, PC3 and DU145) were analyzed by immunoblotting for the Notch1 protein with β-actin as equal 
loading control. (d and e) The same set of cell lines as in the previous panel as well as other human primary prostate epithelial cells (hPEC) 
and immortalized prostate epithelial cancer cells (C1 IM to C45 IM) were analyzed for levels of Notch1 mRNA by real time RT-qPCR. 
Values are in relative arbitrary units after 18s or β-actin normalization. 
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genes up-regulated in PCas with Notch1 levels lower 
than normal prostate tissue (Notch_low ) in the 4 datasets 
analyzed (Figure 2).
We then analyzed the global expression changes 
of LNCaP and PC3 cells in response to acute Notch 
activation by gene profiling with oligo microarrays using 
the Affymetrix platform. Gene network analysis with 
Metacore software revealed that 57% of the network 
objects induced by Notch activation in PC3 and/or LNCaP 
cells (559/982) and 54% of those suppressed by Notch 
activation (460/849) are involved in prostatic neoplasms. 
Furthermore, we found a significant enrichment of 
process networks associated with prostatic neoplasms 
(Table 1), both for induced (Regulation of progression 
through cell cycle, Cell proliferation) and for suppressed 
genes (Inflammatory response, Regulation of progression 
through cell cycle, Cell proliferation). 
Taken together, these results are consistent with a 
putative dual role of Notch1 gene in prostate cancer, where 
it may act both as a tumor suppressor and as an oncogene. 
counteracting effects of notch1 expression on 
prostate epithelial cell growth and tumorigenesis
To demonstrate that Notch1 can act as a tumor 
suppressor in prostate cancer, we assessed the consequences 
Figure 2: Heatmap of prostate tumors and notch1-related genes. Our own gene expression dataset of prostate cancer, named 
Chiorino and three independent ones ([36, 33], TCGA). were analyzed and tumors classified into Notch_low or Notch_high, according 
to Notch1 expression levels in tumors versus healthy controls (blue and yellow horizontal bars, respectively). Unsupervised  hierarchical 
clustering and functional enrichment analysis was performed on genes over-expressed in Notch_high versus Notch_low tumors (black 
vertical bars) and on genes over-expressed in Notch_low versus Notch_high (grey vertical bars).
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of i) decreased Notch1 expression on proliferation of non-
tumorigenic prostate epithelial cells and ii) increased 
Notch1 expression in prostate cancer cells with low Notch1 
levels.
First, immortalized RWPE1 prostate epithelial cells, 
which express Notch1 at high levels, were incubated with 
the γ-secretase inhibitor DAPT to inhibit Notch signaling, 
and this had a positive effect on proliferation by day 10 of 
treatment (Figure 3A). The same cells were infected with 
two retroviruses expressing different shRNAs against 
Notch1 (sh-N1 n°6 and n°7) in parallel with an empty vector 
control. Effective down-modulation of the Notch1 gene also 
in this case caused a substantial increase of proliferative 
potential, as assessed by Alamar Blue cell proliferation as 
well as clonogenicity assays (Figure 3B–3D). 
Conversely, PC3 cells which express Notch1 at low 
levels were stably infected with a retrovirus expressing 
the constitutively active form of Notch1 fused to the 
estrogen receptor (rNERT) [39]. Cells were treated with 
4-hydroxytamoxifen at various concentrations to induce 
translocation of the Flag tagged-Notch fusion protein to the 
nucleus. This caused a parallel increase of the Notch target 
protein HES1, to levels similar to those found in RWPE1 
cells (Figure 3E). The same treatment caused drastic 
growth inhibition of the rNERT expressing cells before 
day 6, as assessed by both Alamar Blue and clonogenicity 
assays (Figure 3F, 3G). We note that even without 
tamoxifen treatment, rNERT expressing cells exhibited 
lower proliferation than the controls, consistent with some 
“leakage” of the Notch fusion protein to the nucleus, and 
consequent effects on downstream HES1 gene expression. 
In parallel experiments, PC3 cells were infected with a 
retrovirus expressing activated Notch1 (hNIC) together with 
green fluorescent protein (GFP) or with a control retrovirus 
expressing GFP alone. The initial fraction of infected cells 
(% of GFP-positive cells) was similar with the two viruses. 
However, already 3 days after cell transduction and by 9 
days of cultivation, there was a progressive decrease in the 
fraction of cells infected with the Notch-GFP virus, while 
the fraction of cells infected with the GFP virus remained 
constant (Supplementary Figure S1A).
To assess whether increased Notch1 activity results 
also in a tumorigenic growth disadvantage in vivo, mice 
were injected subcutaneously with an admixture of PC3 
cells infected with either the activated Notch1 and GFP 
expressing retrovirus, or the virus expressing GFP only, 
admixed with uninfected cells. The tumors formed by 
a mixture of cells infected with the control GFP virus 
and uninfected cells were composed of several large 
areas of GFP-positive cells, distinct from neighboring 
areas composed of GFP-negative cells (Figure 3H). This 
pattern of growth is in agreement with the finding within 
established cancer cell lines, including PC3, of distinct 
sub-populations with different growth and tumorigenic 
potential [40]. When similar experiments were repeated 
with a mixture of cells infected with a retrovirus expressing 
activated-Notch1 together with GFP, little or no GFP-
positive tumor areas were detected, consistent with the 
long term growth suppressing effects of activated Notch1 
in culture (Figure 3H).
table 1: Gene network analysis
networks pValue # network objects
Prostatic Neoplasms 
Inflammatory response
9.151E-03 6 C/EBP, Thrombospondin 1, TGF-beta2, AP-1, Galpha(q)-specif-
ic peptide GPCRs, IL1RN
Prostatic Neoplasms 
Regulation of progression 
through cell cycle
1.445E-02 11 PPAP, BIN1 (Amphiphysin II), Cyclin D2, TGF-beta2, c-Myc, 
AP-1, c-Jun/c-Jun, VEGF-C, c-Jun, PKC, Cyclin D
Prostatic Neoplasms
Cell proliferation
2.465E-02 7 BIN1 (Amphiphysin II), Androgen receptor, TGF-beta2, c-Myc, 
PKC-mu, PKC, Ebp1
Network analysis on genes down-regulated by Notch1 activation in LNCaP and/or PC3 cell lines.
networks pValue # network objects 
Prostatic Neoplasms 
Regulation of progression 
through cell cycle
1.971E-08 26 p21, Casein kinase II, alpha chains, K-RAS, PCNA, IGF-1 re-
ceptor, TGF-beta 1/3, Tcf(Lef), Cyclin A, Skp2/TrCP/FBXW, 
PLK1, Cyclin D1, CDC25, N-Ras, c-Raf-1, b-Myb, CDC20, 
SKP2, RAD9, CDC25B, STAT1, PKC, Brca2, CDK1 (p34), 
FGF1, Casein kinase II
Prostatic Neoplasms Cell 
proliferation
1.521E-04 14 CDC25C, PCNA,  TGF-beta1/3, Skp2/TrCP/FBXW, PLK1, 
CDC25, Amphiregulin, c-Raf-1, Pim-1, CDC25A, SKP2, PKC, 
FGF1
Network analysis on genes up-regulated by Notch1 activation in LNCaP and/or PC3 cell lines.
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Figure 3: Inhibition of notch1 expression in normal prostate epithelial cells enhances cell growth whereas activated 
notch1 expression in prostate cancer cells inhibits growth and tumorigenesis. (A) Immortalized prostate epithelial cells 
(RWPE1) were incubated with the γ-secretase inhibitor DAPT at 10 µM or with DMSO at day 0 and cell proliferation was assayed everyday 
by Alamar Blue assay until day 8. *p < 0.05 (paired student t-test). (b) RWPE1 cells were stably infected with a retrovirus expressing an 
shRNA against Notch1 (sh-N1 n°6 and n°7) or empty vector control (sh-Ct). Notch1 mRNA and protein levels were determined by real time 
RT-qPCR (with 36β4 mRNA for normalization) and immuno-blotting. (c and d) The same stably infected RWPE1 cells were examined 
for their proliferation potential using the Alamar Blue growth/density assay (plating 200 cells per well of a 96 well plate in triplicate) 
(C) or clonogenicity (plating 2000 cells per 6 cm plate in triplicate; staining of dishes 13 days after plating) (D). (e) Prostate cancer 
cells (PC3) were stably infected with a retroviral vector expressing a flag tagged-activated Notch1 protein fused to the human estrogen 
receptor (rNERT), or empty vector control (Neo). Cells were subsequently treated with 4-hydroxytamoxifen (OH-TAM) at the indicated 
concentrations and collected 3 days later. Nuclear extracts were analyzed by immunoblotting with anti-flag antibodies for detection of the 
rNERT protein, which is not recognized by antibodies against endogenous Notch1. Immuno-blotting for TBP was used for equal loading 
control. Total extracts of the same cells were analyzed by immunoblotting for HES1 protein levels, in parallel with RWPE1 cells, using 
β-actin as equal loading control. (F and G) Proliferation of the same PC3 cells as in the previous panels was assessed by Alamar Blue 
growth (F) or clonogenicity (G) assays plus/minus treatment with OH-TAM at the indicated concentrations. Numbers of colonies represent 
the average of triplicate dishes. (H) PC3 cells were infected with retroviruses expressing the activated Notch1 together with GFP or GFP 
alone as control, mixed with uninfected PC3 cells in a ratio 1:3 and injected subcutaneously (in matrigel; 106 cells per injection) into nude 
mice. Four weeks later, tumors were dissected, sectioned and visualized directly by phase contrast and fluorescent microscopy under a 
dissecting microscope. Quantification of GFP positive areas was obtained using the ImageJ software (http://rsb.info.nih.gov/ij) for digitally 
acquired images of 3 different tumors for each combination of cells. Values are expressed as average percentage area of GFP positivity 
versus total tumor area.
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notch growth suppressing effects in prostate 
cancer cells are mediated by p21WAF1/cIP1 in a 
smad3 dependent manner
To better investigate the growth suppressing effects 
of Notch1 in prostate cancer cells expressing low levels of 
this gene, we looked for well-established tumor suppressors 
among the genes induced by Notch1 in PC3 cells. As shown 
in Table 1, tumor suppressor p21WAF1/CIP1 contributes to the 
overrepresentation of “regulation of progression through 
the cell cycle in prostatic neoplasms” within the list of 
genes up-regulated by Notch1. A number of studies have 
shown that expression of p21WAF1/CIP1 is reduced in human 
prostate cancer [41, 42]. Its expression strongly increases 
upon Notch1 upregulation (FC = 3.3 and adjusted p-value 
= 0.0003 in PC3 cells by microarray data, Supplementary 
Table 1). Expression of activated Notch1 (via a construct 
encoding Notch1-ER fusion protein) in PC3 cells followed 
by RT-qPCR analysis confirmed a significant increase of 
p21WAF1/CIP1 levels already at low levels of activated Notch1, 
sufficient for growth suppression (Figure 4A, 4B). To assess 
the functional significance of these findings, PC3 cells were 
infected with retroviruses expressing two different shRNAs 
against p21WAF1/CIP1 in parallel with an empty vector control 
(pRS) (Figure 4C). Cells were subsequently transfected 
with a plasmid expressing activated Notch1 together with 
a selectable marker. Activated Notch1 expression caused 
significant growth suppression, as assessed by colony 
formation, of control cells but not of PC3 cells with p21WAF1/
CIP1 knock-down (Figure 4D).
p21WAF1/CIP1 expression is controlled by multiple 
convergent mechanisms [43]. While p53 is one of its key 
positive regulators, the p53 protein was undetectable in 
PC3 cells (data not shown), consistent with the previously 
reported deletion of the p53 gene in these cells [44]. We 
have previously shown that p63, another p53 family 
member can regulate p21WAF1/CIP1 expression in keratinocytes 
[45]. However, in PC3 cells, p63 silencing did not have 
positive effects on p21WAF1/CIP1 expression (Supplementary 
Figure S1B). Another positive regulator of p21WAF1/CIP1 
expression is Smad3, which was also previously reported 
to be downmodulated in prostate cancer [30, 31, 35, 46–
51]. As with p21WAF1/CIP1, Smad3 levels were up-regulated 
in PC3 cells by activated Notch1 expression (FC = 2.9 
and adjusted p-value = 0.001 in PC3 cells by microarray 
data, Supplementary Table 1). Using the inducible Notch1 
expression system, Smad3 mRNA and protein expression 
were found to increase in PC3 cells in a dose-dependent 
manner paralleling induction of p21WAF1/CIP1 (Figure 4E, 4F). 
Transfection of these cells with a Smad3 expression vector 
caused induction of p21WAF1/CIP1 expression (Figure 4G) 
while, conversely, knock-down of Smad3 by infection with 
shRNA retroviruses (pRS-Smad3 n°1 and n°2) showed that 
induction of p21WAF1/CIP1 by activated Notch1 is Smad3-
dependent (Figure 4H).
Nucleotide sequence analysis revealed the presence 
of numerous fully conserved CSL binding sites dispersed 
throughout the promoter and the large (> 100 kb) first 
intronic region of the Smad3 gene to which the rNERT 
fusion protein was found to bind in a 4-hydroxytamoxifen 
dependent manner (Figure 4I). To assess whether this gene 
is induced as a primary consequence of increased Notch1 
signaling and consequent activation of the transcription 
factor CSL, PC3 cells expressing the rNERT fusion protein 
were treated with 4-hydroxytamoxifen only for 24 hours, 
at a time when p21WAF1/CIP1 expression was not yet induced 
(data not shown). As shown in Figure 4J, unlike p21, 
Smad3 transcription was already induced even when new 
protein synthesis was inhibited by cycloheximide prior 
treatment (Figure 4J).
To confirm our findings in the clinical setting, we 
analyzed Notch1, p21WAF1/CIP1 and smad3 co-occurrence in 
the TCGA-PRAD dataset and found that Notch1 association 
with Smad3 was positive and statistically significant 
(p-value = 0.002) and that Notch1 showed a tendency 
towards co-occurrence with p21WAF1/CIP1 (p-value = 0.04).
Taken together, these data indicate that Notch 
growth suppressing effects in prostate cancer cells with 
low Notch1 levels are mediated by p21WAF1/CIP1 in a Smad3 
dependent manner.
notch-dependent expression of pro-oncogenic 
genes in prostate cancer cell lines resistant to 
notch growth inhibition
As previously said, several published prostate 
cancer datasets contain samples with upregulated 
Notch1 expression compared to normal prostate tissue. 
Furthermore, we showed in 4 independent prostate 
cancer patient cohorts that tumors with high Notch1 
expression are enriched in GO terms as neurogenesis, 
response to estrogen stimulus and cell migration. To better 
understand the putative tumor promoting role of Notch1 
in these prostate samples, we crossed Notch1-induced or 
repressed genes in PC3 and/or LNCaP cells with the genes 
differentially expressed in tumors according to Notch1 
levels in at least 3 independent datasets (Supplementary 
Table 2). Indeed, among the genes induced by Notch1 in 
cells and up-regulated in tumors with high Notch1 levels, 
besides the Notch1 target HES1, we found many genes 
with tumor-promoting functions. Conversely, among the 
genes inhibited by Notch1 in cells and down-regulated in 
Notch_high PCas there were targets with tumor suppressing 
function in prostate cancer (Table 2). 
An attractive possibility suggested by the above 
findings is that there may be an in vivo selection for 
prostate cancer cells resistant to Notch growth inhibitory 
effects that have retained Notch-induced up-regulation of 
pro-oncogenic genes. We reasoned that a similar situation 
may be reproduced and tested in vitro. PC3 cells were 
stably transduced with activated Notch1 retroviruses in 
parallel with controls and cells were selected. Out of the 
majority of prostate cancer cells that are growth arrested 
by activated Notch1 expression, we were able to select a 
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Figure 4: p21WAF1/cip1 mediates notch1-induced growth arrest and is controlled by notch1 through a smad3 dependent 
mechanism. (A and b) PC3 cells stably infected with a retroviral vector expressing the flag tagged-activated Notch1 protein fused to the 
human estrogen receptor (rNERT), or control virus (Neo) were treated for 3 days with 4-hydroxytamoxifen at the indicated concentrations. 
Expression of p21WAF1/Cip1 was analyzed by real time RT-PCR (using 36β4 mRNA for normalization) (A) and by immuno-blotting (B). 
(c) PC3 cells were stably infected with a retrovirus expressing an shRNA against p21WAF1/Cip1 (pRS-p21 n°1) or empty vector control (pRS). 
Cells were subsequently transfected with an expression vector for activated Notch1 (hNIC) together with a neomycin resistance gene, or 
empty vector control (ctrl). Twenty four hours later, cells were analyzed by immuno-blotting for p21WAF1/Cip1 expression, with β-actin for 
normalization. (d) PC3 cells plus/minus p21WAF1/Cip1 knock-down and activated Notch1 expression as in the previous panel were replated 
(at 8 hours after transfection) at low density in triplicate dishes (1000 cells per 6 cm dish) in the presence of neomycin for selection of 
transfected cells. Numbers of colonies per dish were counted 10 days later. (e and F) The same PC3 cells with inducible Notch1 activity 
as in (A and B) were analyzed for Smad3 expression by real time RT-PCR (using 36β4 mRNA for normalization) (E) and immunoblotting 
(F). (G) PC3 cells were transiently transfected with an expression vector for Smad3 (Smad3) or empty vector control (ctrl) for 48 hours, 
followed by immunoblot analysis of p21WAF1/Cip1 and β-actin proteins. (H) PC3 cells were stably infected with a retrovirus expressing shRNA 
against Smad3 (pRS-Smad3 n°1) or empty vector control (pRS) and subsequently infected with an activated Notch1 expressing adenovirus 
(AdN1) or GFP-expressing control (ctrl). Twenty four hours later, cells were analyzed by immunoblotting for levels of Smad3 and p21WAF1/
Cip1 proteins with β-actin for normalization. (I) The same PC3 cells with inducible Notch1 activity as in (A and B) were processed for 
chromatin immunoprecipitation with antibodies specific for flag or non-immune IgG control followed by PCR amplification (50 cycles) 
of various regions of the Smad3 promoter as indicated in the schematic above. The sequences of the two predicted RBP-binding sites 
(CSL-A and CSL-B) are, respectively, 5′-CTAATGGGAAAATAA-3′ and 5′-GGGGTGGGAGATTCC-3′. Un-precipitated chromatin 
preparations were similarly analysed and used as “input DNA” control. Binding of the rNERT-flag fusion protein to its two predicted 
CSL binding sites in the Smad3 promoter was quantified by chromatin immuno-precipitation assay and real time PCR. The amount of 
precipitated DNA was calculated relative to the total input chromatin, and expressed as percentage of the total according to the following 
formula (Frank et al. 2001) : % total = 2∆Ctx5 where ∆Ct = Ct (input)-Ct (immuno-precipitation). Ct: cycle threshold. (J) PC3 cells 
expressing the rNERT fusion protein were treated, in parallel with control cells (Neo), for 24 hours with 4-hydroxytamoxifen in presence 
or absence of cycloheximide (CHX, 10 mg/ml, added 2 hours before 4-hydroxytamoxifen treatment). Expression of Smad3 (left panel) and 
p21WAF1/Cip1 (right panel) was analyzed by real time RT-PCR (using 36β4 mRNA for normalization). 
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few colonies that kept proliferating. As shown in Figure 
5A, some such clones effectively lost Notch1 expression 
while some retained high Notch1 protein levels. For 
subsequent analysis, we chose 2 Notch1 “resistant” clones 
arising from stably infected PC3 cells with MSCV-Notch1 
and subsequently selected with neomycin and 1 arising 
from stably infected PC3 cells with pinco-Notch1-GFP 
selected for GFP expression. RT-qPCR analysis of CXCL6 
and EPAS1, two tumor promoting genes significantly 
more expressed in human prostate cancer versus normal 
tissue [52, 53] and induced by Notch1 in LNCaP and PC3 
cells (Supplementary Table 2), were also found highly 
transcribed in the Notch1 resistant clones, like in the 
in vivo tumors with elevated Notch expression (Figure 5B). 
Furthermore, expression levels of these genes were not 
affected by knocking down p21WAF1/CIP1 in PC3 cells, 
indicating that while certain tumor suppressor genes are 
under p21WAF1/CIP1 control, the pro-oncogenic Notch target 
genes might escape from this control (Figure 5C). This 
possibility deserves further investigation to functionally 
describe a mechanism.
dIscussIon
Among the distinguishing features of prostate 
tumors are their slow development and multi-focality 
that point to an interplay between cells of origin, genetic 
and epigenetic alterations in the developing cancer cell 
population and changes in the surrounding environment 
[2]. Mechanisms underlying the balance between growth 
and differentiation of tumor stem cells are likely to depend, 
at least in part, on developmental pathways functional also 
in normal tissues. We addressed this question as it relates 
to the role of Notch signaling in this context. 
In contrast to the tumor promoting function 
commonly attributed to this pathway in mammalian 
cells, our prior work demonstrated that Notch signaling 
contributed in suppression of mouse and human 
keratinocyte tumor development, by essentially affecting 
global control of gene expression and differentiation [18, 
19, 54]. As for prostate cancer, contrasting reports exist 
[22–26, 55]. Our present findings indicate that Notch 
signaling appears to exert a similarly important tumor 
growth and suppressing function in the prostate. More 
specifically, we found that Notch1 overexpression in 
prostate cancer cell lines both induces and inhibits gene 
networks associated with cell cycle and proliferation in 
prostatic neoplasms. Furthermore, by comparing several 
PCa datasets with a focus on Notch1 expression in tumor 
vs normal prostate tissue, we found that the majority of 
samples was expressing low Notch1 levels. On the contrary, 
some others were displaying higher levels as compared 
table 2: list of tumor promoting/suppressing genes that are induced/repressed by activated 
notch1 in Pc3 and or lncaP cells and concomitantly differentially expressed in prostate tumors 
according to notch1 levels
tumor promoting genes up-regulated in notch-high Pcas and induced by notch1
symbol Gene name reference
HES1 hes family bHLH transcription factor 1 PMID: 24684754
EPAS1 endothelial PAS domain protein 1 PMID: 21372204
ATP1B1 ATPase, Na+/K+ transporting, beta 1 polypeptide PMID: 21919029
ZFP36L1 ZFP36 ring finger protein-like 1 PMID: 20802528
SNAI2 snail family zinc finger 2 PMID: 20506051
OAT ornithine aminotransferase PMID: 18202758
MAP3K8 mitogen-activated protein kinase kinase kinase 8 PMID: 21267413
CXCL6 chemokine (C-X-C motif) ligand 6 PMID: 23536554
ID1 inhibitor of DNA binding 1, dominant negative helix-loop-helix protein PMID: 23342268
PMID: 17177845
PMID: 15041724 
PMID: 15905202
PMID: 12016143
tumor suppressing genes down-regulated in notch-high Pcas and inhibited by notch1
symbol Gene name reference
SLC27A2 solute carrier family 27 (fatty acid transporter), member 2 PMID: 19781100
ENDOD1 endonuclease domain containing 1 PMID:  21829708
CCNG2 cyclin G2 PMID: 24293374
NEDD4L neural precursor cell expressed, developmentally down-regulated 4-like, E3 ubiquitin protein ligase
PMID: 19004604
PMID: 14615060
Oncotarget48020www.impactjournals.com/oncotarget
to the normal counterpart. Bioinformatic comparison 
between Notch1_low and Notch1_high prostate tumors 
in four independent datasets allowed characterization of 
the gene networks overrepresented in the two subgroups: 
nucleosome assembly and fatty acid metabolism in 
Notch1_low tumors and EMT, cell migration, angiogenesis 
and neurogenesis in Notch_high tumors, respectively. 
Then, in normal prostate epithelial cells endogenously 
expressing Notch1 at high levels, consequences of knock 
down resulted in enhanced cell growth, while induction 
of activated Notch1 in prostate carcinoma cells derived 
from Notch1_low tumors caused cell growth inhibition 
and suppressed tumorigenicity. Accordingly, increased 
Notch activity was sufficient to suppress tumorigenicity of 
aggressive PC3 prostate cancer cells. 
Downstream of Notch activation, we showed that 
p21WAF1/CIP1 is a key target gene that mediates growth 
suppression even in prostate cancer cells with mutated 
and/or deleted p53. Smad3, previously reported to 
regulate p21WAF1/CIP1 expression and to functionally and/or 
biochemically interact with Notch [56], is itself a primary 
transcriptional target of Notch in prostate cells. Down-
Figure 5: Prostate cancer cell lines resistant to notch growth inhibition overexpress the oncogenic genes ePAs1 
and cXcl6 regardless of p21WAF1/cip1 expression levels. (A and b) PC3 prostate cancer cells stably transduced with MSCV-
neo-Notch1(neoN1) or pinco-Notch1 (pincoN1) versus respective controls were grown at low density and after 10 days, resistant clones 
were collected individually, expanded and analyzed by immuno-blotting for Notch1 expression (A) or by RT-qPCR for expression of the 
indicated genes (B). (c) PC3 cells stably transduced with the rNERT versus neo control were subsequently stably infected with a retrovirus 
expressing an shRNA against p21WAF1/Cip1 (pRS-p21, +) or empty vector control (pRS, −) and treated with 4-hydroxytamoxifen (OH-TAM) 
at 0, 0.3 and 1 µM and collected 2 days later. Expression of the indicated genes was analyzed by RT-qPCR with 36β4 for normalization.
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modulation of the Notch pathway in tumors does not 
correlate with histological grade of the lesions, suggesting 
that it may occur as a relatively early event, prior to the 
acquisition of a more malignant behavior. Consistently, 
in Tomlins [31] we found decreased expression of the 
Notch1 gene already in precursor lesions of prostate 
cancer (HGPIN). However, permanent down-modulation 
of the Notch pathway is also likely to be required for 
tumor development, as decreased Notch1 expression 
has been found also at late stages of cancer progression 
[30, 31]. In keeping with that, in our own dataset with 
a follow-up of more than 10 years, tumors associated to 
poor outcome were enriched in both Notch_high and in 
Notch_low samples (data not shown). 
Previous studies showed that Notch1 is specifically 
expressed in myoepithelial cells of the basal layer of the 
prostate gland, while it is down-modulated in luminal cells 
[57]. Valdez and collaborators [58] discovered a positive 
feedback loop between stromal TGFβ and Notch signaling 
in basal cells, which appears to diminish prostate growth 
by limiting basal cell proliferation. In an experimental 
mouse model characterized by conditional deletion of 
the Notch1 gene, increased prostate cell proliferation and 
deranged differentiation with features resembling those of 
early neoplastic lesions [22] were found. The fact that the 
vast majority of prostate cancers usually display luminal as 
well as basal cell markers suggests that these cancers arise 
from stem cells that are at an early stage of commitment to 
differentiation [20, 21]. In this case, one would expect that 
aberrant or down-modulated Notch signaling is required 
for cancer development, an expectation supported by our 
findings.
In the present report we could also show that 
prostate cancer cells resistant to Notch1 growth inhibitory 
effects retain Notch-induced upregulation of pro-
oncogenic genes also found in Notch_high tumors. This 
was the case of resistant PC3 clones, with high levels of 
Notch1 and of Notch1-induced targets: CXCL6, already 
found overexpressed in bone-tropic phenotypes where 
skeletal colonization is favored [51], and EPAS1, a 
hypoxia-inducible factor that promotes tumorigenesis, 
angiogensis, and metastasis by direct interaction with the 
8q24 prostate cancer locus [52]. Our hypothesis is that, 
once such cells have escaped from p21-mediated Notch 
growth inhibition, they become more tumorigenic, in a 
context where many other important pathways are already 
deranged, thus favoring EMT and migration. In line 
with this, a previous study suggested a role for Notch1 
signaling in the acquisition of an aggressive phenotype 
and Notch_high tumors were found enriched in both EMT 
and cell migration [59].
Taken together, our results can reconcile different 
and apparently contrasting results on the role of Notch1 
in prostate cancer and suggest that Notch1 inhibition 
as therapy for this malignancy should be carefully 
contextualized by analyzing Notch1 expression in cancer 
cells and in their surrounding microenvironment.
MAterIAls And MetHods
cell culture, viruses and plasmids
By prostate epithelial cells (PrEC and hPEC) 
were obtained respectively from Cambrex and Dr M. 
Laiho (Helsinki, Finland) and maintained in PrEBM 
supplemented with bovine pituitary extract, epidermal 
growth factor, insulin, transferring, hydrocortisone, 
retinoic acid, epinephrine, triiodothyronine, and 
gentamicine-amphotericin solution (Cambrex). The short 
term cultured prostate cancer cell lines C1 IM to C45 
IM were a gift of Dr A. Farsetti (Roma, Italy) and were 
isolated and cultured as described previously [60]. All 
other cancer cell lines were obtained from the ATCC and 
cultured as recommended by the ATCC. The plasmids 
rNERT-neo and neo were kindly provided by Dr U. Just 
(Christian-Albrechts-University of Kiel, Germany), 
the plasmids pSI-MSCV-CLPpuro-H1R-NotchRi6 and 
pSI-MSCV-CLPpuro-H1R-NotchRi7 (respectively sh-
N1 n°6 and n°7, in the text) and control (sh-Ct) by Dr. 
T. Kiyono (National Cancer Center Research Institute, 
Tokyo) and the plasmid MSCV-neo-Notch1 and control 
by Dr C. Brisken (EPFL, Switzerland). The pRS-p21 n°1 
and n°3 plasmids were respectively from Drs. R. Agami 
and R. Bernards (Dutch Cancer Research Institute), 
and the pRS-Smad3 plasmids from X-H Feng (Baylor 
College of Medicine). The pinco-Notch1 plasmid was 
obtained by inserting the cDNA of activated Notch1 
(from digestion of the pcDNA3/hNIC by BamHI/XhoI) 
into the BamHI/EcoRI sites of the pinco-GFP vector [61]. 
Retroviruses were amplified in 293T packaging cells and 
the supernatant containing the viral particles was used to 
infect the cells during one hour together with polybren. 
Infection with the adenoviruses Ad-GFP, Ad-Notch1 
and Adp53 was performed as previously described [62]. 
For transfection, cells were incubated in presence of a 
mixture of lipofectamine 2000 (Invitrogen) according to 
the manufacturer’s protocol and either pcDNA3/hNIC, 
pcDNA3-flag-Smad3 or control plasmid. The plasmid 
expressing pcDNA3-flag-Smad3 was a gift of P. Ten 
Dijke (Leiden University Medical Center). For RNA 
transfection, cells were incubated in presence of a mixture 
of Interferin (Polyplus) according to the manufacturer’s 
protocol, with the following siRNAs: sip63 n°1: 5′- 
GCACACAAUUGAAACGUACAGGCAA-3′, sip63 n°2: 
5′-ACCAUGAGCUGAGCCGUGAAUUCAA-3′ or the 
siRNA control (Stealth siRNA, Thermo Fisher Scientific). 
4-hydroxytamoxifen was purchased from Sigma and 
resuspended in 95% ethanol to make 1 mM stock solution, 
stored at –80°C.
Prostate samples and laser capture 
microdissection (lcM)
Prostate cancer tissue samples containing at least 
70% of neoplastic cells were obtained from 67 patients 
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(age range: 50–75 years) who had undergone radical 
prostatectomy at the Hospital of Biella (Italy) and prostate 
biopsies were obtained from 10 healthy patients of the 
same age range, without any diagnosis of prostate tumor 
or BPH. All patients gave informed consent and the 
study was approved by the Ethical committee of Regione 
Piemonte. LCM was performed using an Arcturus XT 
microdissection system (Applied Biosystems, Carlsbad, 
CA, USA) as before [63].
Alamar blue, clonogenicity and tumorigenicity 
assays
For Alamar Blue assay, cells were seeded at a 
density of 100 cells (for PC3 cells) or of 200 cells (for 
RWPE1 cells) per well of a 96 well plate in triplicate and 
cells density was further evaluated at the indicated days 
by incubating cells for two hours with the Alamar Blue 
Reagent according to the manufacturer’s instructions 
(Biosource). Fluorescence excitation was performed 
at 544 nm and the emission was read at 590 nm on a 
fluorimeter (Molecular Devices). For cell survival assay, 
PC3 cells were transduced with a retroviral vector over-
expressing Notch1 and GFP (MSCV-N1-GFP) or GFP 
alone (MSCV-GFP) as control. At days 2, 3, 6 and 9 
after transduction, cells were trypsinized and % of GFP 
positive cells over total cells was determined by counting. 
For clonogenicity assay, cells were seeded at a density 
of 1000 cells (for PC3 cells) or 2000 cells (for RWPE1 
cells) per 6-cm culture plates. Ten (for PC3 cells) or 13 
(for RWPE1 cells) days later, cells were washed with PBS, 
fixed in 100% ethanol and stained in 0.1% crystal violet 
overnight before washing. For tumour formation in mice, 
cells were collected and 106 cells were mixed with 70 μl of 
Matrigel (BD Biosciences) before subcutaneous injection 
in nude mice. Four weeks after, tumors were dissected, 
and analyzed by fluorescent microscopy.
Quantitative real time Pcr (rt-qPcr), chIP 
assay and microarray hybridization
RT-qPCR and ChIP assays were performed as 
previously described [18] and the list of specific primers 
used for this study is provided in Supplementary Table S3.
For microarray hybridization of LNCaP and PC3 
cell lines plus/minus Notch1, total RNA (5–8 μg) was 
used as template for double stranded cDNA preparations 
with T7-(dT)24 oligonucleotide primers for the first strand 
reaction. The resulting cDNAs were used for preparation of 
biotin-labeled cRNA probes preparation and hybridization 
to the Affymetrix U95 Av2 gene expression platform 
containing 12,626 probe sets according to manufacturer’s 
recommendation (two chips per sample were generated, 
following manufacturer’s instructions).
For prostate tissue microarray hybridization, prostate 
tumor (n = 67) and normal prostate (n = 10) tissues were 
co-hybridized with a commercial pool of RNA from organ 
donor healthy prostates (Becton Dickinson). Tissues were 
homogenized (Ultra – TurraxT8, Ika – Werke) and totRNA 
was isolated following TriReagent (Sigma Aldrich) 
protocol. mRNA was amplified by means of Amino Allyl 
MessageAmp I or II aRNA Kit (Ambion Inc.), according to 
manufacturer’s protocol; only one round of amplification 
was performed. Labeling was performed using NHS 
ester Cy3 or Cy5 dies (Amersham, GE Healthcare) able 
to react with the modified aaRNA. The same quantity 
of differentially labeled sample and reference was put 
together, fragmented and hybridized to oligonucleotide 
glass array with sequences representing 27,958 Entrez 
Gene RNAs and 7,419 lincRNAs (Human Gene 
Expression 8 × 60K Microarray, Agilent Technologies). 
After the hybridization step, slides were washed following 
Agilent procedure and scanned with the dual-laser Agilent 
scanner G2505C. For each experiment, a dye-swap 
replicate was performed. totRNA and mRNA quality, 
quantity and labeling were checked by Agilent 2100 
bioanalyzer and NanoDrop ND-1000 Spectrophotometer 
(Thermo Scientific).
Microarray analysis
Raw Affymetrix CEL files were loaded into R 
and analyzed with RMA (Robust Multichip Average). 
The LIMMA (LInear Models for Microarray Analysis) 
package was then used to identify differentially expressed 
genes upon Notch1 activation. Data can be retrieved from 
GEO # GSE74631.
Agilent images were analyzed using the Feature 
Extraction software (Agilent Technologies). Raw 
data elaboration was carried out with Bioconductor 
(www.bioconductor.org) [64] using R statistical 
language. Background correction was performed with 
the normexp method with an offset of 50, loess was 
used for within-array normalization and A-quantile for 
between-array normalization. Data can be retrieved from 
GEO #GSE60329.
Additional publicly available gene expression 
array data were obtained from GEO (http://www.
ncbi.nlm.nih.gov/geo/) and from TCGA (The Cancer 
Genome Atlas) Research Network. The Ambs’ raw .CEL 
files were loaded into R and analyzed with RMA (Robust 
Multichip Average). For Taylor’s dataset, processed 
data by the authors were used. TCGA data on prostate 
adenocarcinoma were analyzed with the edgeR package 
of Bioconductor.
The LIMMA (LInear Models for Microarray 
Analysis) package was then used to identify genes 
differentially expressed in Notch_low versus Notch_high 
tumors. The empirical Bayes method was used to compute 
a moderated t-statistics [65]. p-values were adjusted for 
multiple testing by using a false discovery rate (FDR) 
correction (Benjamini and Hochberg method).
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Images were analyzed using the feature 
extraction software (agilent technologies)
Raw data elaboration was carried out with 
Bioconductor (www.bioconductor.org) [64] using R 
statistical language. Background correction was performed 
with the normexp method with an offset of 50, loess was 
used for within-array normalization and A-quantile for 
between-array normalization. Data can be retrieved from 
GEO # GSE60329.
Additional publicly available gene expression 
array data were obtained from GEO (http://www.
ncbi.nlm.nih.gov/geo/) and from TCGA (The Cancer 
Genome Atlas) Research Network. The Ambs’ raw. 
CEL files were loaded into R and analyzed with RMA 
(Robust Multichip Average). For Taylor’s dataset, 
processed data by the authors were used. TCGA data on 
prostate adenocarcinoma were analyzed with the edgeR 
package of Bioconductor.
The LIMMA (LInear Models for Microarray 
Analysis) package was then used to identify genes 
differentially expressed in Notch_low versus Notch_high 
tumors. The empirical Bayes method was used to compute 
a moderated t-statistics [65]. p-values were adjusted for 
multiple testing by using a false discovery rate (FDR) 
correction (Benjamini and Hochberg method).
Go enrichment and network analysis
In order to look for any overrepresented biological 
processes (BP5) of the Gene Ontology (GO), we used 
the functional annotation tool available within DAVID 
Website (http://david.abcc.ncifcrf.gov/), using the lists of 
differentially expressed genes in prostate tumors versus 
healthy control samples. 
MetaCoreTM version 6.23 (Thomson Reuters) 
was used for network analysis, that was applied to 
differentially expressed genes differentially expressed in 
LNCaP and PC3 cells upon acute Notch activation.
Western blot
Total proteins were extracted as previously 
described [66]. Nuclear extracts were prepared as 
followed: cells were first lysed for 5 minutes in L1 
buffer (50 mM Tris pH 8.0, 2 mM EDTA, 0.1% NP-40, 
10% Glycerol) supplemented with proteases inhibitors. 
Nuclei were then pelleted at 3000 rpm in microfuge and 
resuspended in L2 buffer (50 mM Tris pH 8.0, 1% SDS, 
5 mM EDTA).Immunodetection of Notch1, Flag, HES1, 
p21WAF1/CIP1, Smad3, TATA-box binding protein (TBP) 
and β-actin was performed using the primary antibodies 
sc-6014 (Santa-Cruz), F-3165 (Sigma), HES1 (gift 
of T. Sudo),sc-6246 (Santa-Cruz), 51–1500 (Zymed 
Laboratories), ab-818 (Abcam) and sc-1616 (Santa-Cruz) 
respectively.
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